Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis

An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

Ganesh Raghu, Harold R. Collard, Jim Egan et al. · American Journal of Respiratory and Critical Care Medicine · 2011 · 7.3K citations · Full text

Medicine, Clinical Sciences, Internal Medicine +17

Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis

Luca Richeldi, Ulrich Costabel, Moisés Selman et al. · New England Journal of Medicine · 2011 · 1.2K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

BIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy

Frank Hilberg, Gerald J. Roth, Martin Krššák et al. · Cancer Research · 2008 · 1.1K citations · Full text

Medicine, Oncology, Pharmacology +17

Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent

Mark S. Wilson, Satish K. Madala, Thirumalai R. Ramalingam et al. · The Journal of Experimental Medicine · 2010 · 734 citations · Full text

Veterinary Medicine, Immunology, Pathology +17

Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features

D. S. Kim, Joo Hun Park, B. K. Park et al. · European Respiratory Journal · 2005 · 498 citations · Full text

Medicine, Clinical Sciences, Pathology +16